{"data":{"type":"company_profile_ai","id":151208,"entity_id":"wefunder:company:151208","attributes":{"canonical_url":"https://wefunder.com/quantgene","retrieval_urls":{"canonical":"https://wefunder.com/quantgene","json":"https://wefunder.com/quantgene.json","markdown":"https://wefunder.com/quantgene.md","ai_json":"https://wefunder.com/quantgene.ai.json","ai_text":"https://wefunder.com/quantgene.ai.txt","changelog_json":"https://wefunder.com/quantgene.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-15T23:52:11Z","generated_at":"2026-06-16T02:04:52Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":false,"privacy_mode":"unlisted","invite_only":false},"company":{"id":151208,"entity_id":"wefunder:company:151208","slug":"quantgene","name":"QUANTGENE","tagline":"Ending Cancer with Intelligent Genomics","location":"Portland, OR","website":"https://quantgene.com/","total_amount_raised":0,"total_investors":0,"is_funded":false,"is_active":false},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 0","citation":"https://wefunder.com/quantgene#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T23:52:11Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-16T23:52:11Z"},{"claim_id":"claim-total-investors","text":"Total investors: 0","citation":"https://wefunder.com/quantgene#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T23:52:11Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-16T23:52:11Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 0","citation":"https://wefunder.com/quantgene#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T23:52:11Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-16T23:52:11Z"},{"claim_id":"claim-total-investors","text":"Total investors: 0","citation":"https://wefunder.com/quantgene#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T23:52:11Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-16T23:52:11Z"}],"company_claims":{"tagline":"Ending Cancer with Intelligent Genomics","story":"Engage! Join our live town halls on X (Twitter) every week: CLICK HEREBook a 1:1 meeting with our Founder \u0026amp; CEO if you are considering an investment of $10k or more: https://calendly.com/johannesbhakdi/1-1-with-jo-bhakdi Invest $1,000 and get $500 off QX cancer screening. It can save your life: $1,495 instead of $1,995. How it works: 1) invest $1,000 or more. 2) Write us an email to qx@quantgene.com 3) We will send you your investor discount code and link to QX checkout. Qx is available in the United States across all states except New York. Our products save lives. Quantgene Qx is the world’s first medical solution that intelligently detects cancer signals across a wide range of diagnostic signals. It combines Quantgene’s genomics platforms with a new medical intelligence engine that uses the patient’s medical history, family history, preventive screening status as well as advanced imaging data (if available) to triangulate signals of over 50 cancer types at an unprecedented level of precision. Based on our early pilot programs, we are confident that with the first 1,000 Qx customers we will be able to show the highest cancer detection rate ever achieved. Many of the nation’s leading cancer screening experts are watching us. We have good reason to believe Qx won’t disappoint.\u0026nbsp;Get Qx HERE Quantgene’s Intelligent Genomics has already started saving lives. Ask Ashley, whose breast cancer was detected by Quantgene’s Qx system in an early commercial pilot. Ashley is 39, too young for standard of care preventive cancer screenings. We know that there are thousands of patients like Ashley out there. These patients need Qx. Get Qx HERE Once we hit our 1,000 patient milestone in 2024, Qx is on its way to END CANCER. Our solutions transform hospitals.Quantgene Qi is the world’s first turnkey solution to bring precision genomics inside hospital systems. Qi turns isolated genetic test ordering into a seamless hospital solution: it combines laboratory infrastructure, cloud \u0026amp; bioinformatics as well as revenue cycle management and clinical implementation. Qi is a holistic system that unlocks new revenue streams for hospitals while expanding clinical staffing and improving patient care. Through an intelligent commercial management system, Qi is fully paid for and adds to the bottom line of hospitals instead of draining already tight budgets. If you are part of the medical or administrative leadership of a hospital, learn more about Qi here. Qi isn't a theory. It's a system whose components have already been vetted by clinical decision makers in some of the world's best hospital and cancer systems. Pre-launch, we already have 6 deals on the table, each of which would set a new standard for genomic medicine in America. The reason is simple: Patients need Qi and Hospitals WANT Qi. Once we close the first deals in 2024, Qi creates a new genomics infrastructure designed to REACH 1 BILLION PATIENTS within a decade. We are ready for prime time. After 8 years of R\u0026amp;D, we have prepared two platforms that have the potential to end cancer as we know it: Qi for hospitals and Qx for patients. For Qi, our hospital deal pipeline already exceeds $200mm in deal value. For Qx, we reached distribution partnerships in 2023 that allow us to reach over 70,000 qualified patients in 2024.\u0026nbsp;Our Intelligent Genomics platform is now ready for patients. That's a very big deal. It took us 8 years and $36mm in R\u0026amp;D investments to get to this point, and we are very proud of it. In our commercial pilots, we already saved the first life (read Ashley's story below). Our technology is tested and mission-focused.Quantgene's Intelligent Genomics platforms have come a long way since 2015. $36mm and a focused effort went into the construction of the Alpha Lab with the first unified intelligent genomics sample workflow, Quantgene’s DeepGen genomic cancer detection system covered in many peer-reviewed publications, as well as 100s of proprietary technology components that bring everything together under one purpose: to end cancer for all.The Quantgene Alpha Lab in Portland, OR is the world’s first genomics laboratory with a unified workflow across cfDNA multi-cancer signal detection, hereditary cancer genetics and pharmacogenomics. This allows us to achieve lower cost per sample at improved quality and patient convenience compared to conventional genomics workflows - a game-changer for delivering seamless and affordable Intelligent Genomics to all.\u0026nbsp;Our R\u0026amp;D team of PHDs and engineers in Berlin, Germany leads the world in Intelligent Genomics system design. Their work allows us to transcend conventional genomics by combining multiple genomic cancer signals with other modalities, including far-reaching patient and family history, preventive screening status and advanced imaging results to detect cancer with a new level of precision.\u0026nbsp;We work with the best. Our cancer genomics research includes collaborators like Prof. Raz, Prof. Chambers and other clinicians who are working at some of the world’s leading cancer centers.\u0026nbsp;Their passion and expertise have helped us to create one of the world's most advanced clinical genomics platforms. Our expert advisors. investors and partners work at the nation’s premier clinical diagnostics and disruptive investment firms. Their advice and support remains crucial to our success. Our team is committed to win - for You. Our team is our greatest asset. With backgrounds from some of the world’s leading genomics companies and research institutions, we have proven that we are the only team in the industry that has the cohesion, expertise and determination to get the job done. For 8 years, Quantgene has pushed the frontier of Intelligent Genomics with only one goal in mind: to END CANCER. Our market exceeds $1 Trillion. Cancer is killing 1,600 Americans every single day. It destroys over $1T in economic value each year. Cancer diagnostics alone are a $132 billion market. Our Qx and Qi solutions can quickly reach the 30 million Americans most in need for genomic cancer protection, either through existing insurance coverage (Qi) or self-pay concierge care (Qx). With each of us currently having a 30% chance of dying of cancer, it’s an opportunity we have to seize. Our competition got stuck with special interests.In certain industries, you get paid to fail. Over the last 8 years, we have seen again and again how great technologies got sold, got stuck or got pivoted away from patients. Universal Cancer detection and intelligent genomics is not just a race for technology: it's also a fight for independence from special interests. Quantgene is the only leading genomics company that has remained in control of its own fate. Yes, we have an outstanding team and technology platform - but the real reason we are ready to launch is because special healthcare interests weren't able to stop us. Believe us, they have tried. We project $1 billion in revenue by 2028.We have tested and calibrated our solutions extensively over the last 2 years. In 2024, we want to bring personal cancer protection to the first 1,000 customers and implement the first 2 Qi solutions in hospitals. Both solutions are profitable from the outset, with 40%+ gross margins and enormous TAMs. A successful 2024 commercial launch can put Quantgene on track to become the fastest-growing, highest-grossing healthcare company in the world, with over $1 billion cumulative revenue within the next five years. In order to become the fastest-growing healthcare company, we have to succeed in 2024. We need your support so we can acquire the first 1,000 Qx members who receive next-generation genomic cancer detection; and to close \u0026amp; implement the first 2 Qi hospital deals valued at ~$100mm combined revenue over the next five years. With these numbers, we also project to detect 10 early stage cancers and save our patient’s lives.Praised by the press.Don't let them stop us. In our conversations with institutional healthcare and biotech investors, we have noticed a pattern: they love our technology, but hate the idea to commercialize them. Instead, they push us to change direction, add more data and prepare the company for sale to a large pharma or diagnostics conglomerate. They say that's the “proven path” for new genomics technologies. But we deeply disagree. Intelligent Genomics is now ready to save countless lives. We can't just sell out and see it being shelved in a corporate basement. If we want to stay true to our mission and KILL CANCER, we NEED to unlock an independent capital source. We need YOU to help us build the first healthcare company funded BY the people, so we can work FOR the people.\u0026nbsp;Regardless if you want to become a Quantgene investor or not, please join us here to learn more about the problem of special interests in cancer innovation. It affects all of us. Invest and make history. Intelligent Genomics is opening a path into a future where cancer has ceased to be a major risk of death. There is not much doubt in the medical community that universal cancer detection would achieve this goal. Quantgene is the only company ready to open the path into this future. Please help us to get there. We invite you to invest in Quantgene. By joining us, you are investing in one of the greatest opportunities and innovation leaps of our time: the End of Cancer. Join our journey to create the first independent healthcare innovation company, push the frontiers of genomic intelligence and KILL CANCER. Book a 1:1 meeting with the CEOIf you are considering an investment of $10k or more, you can book a 1:1 meeting with Quantgene's Founder \u0026amp; CEO Jo Bhakdi here: https://calendly.com/johannesbhakdi/1-1-with-jo-bhakdi","quick_facts":["Realized $50mm in revenue.","Combines genomics, AI and medical intelligence technology for universal cancer detection.","Pole position to disrupt the $168B cancer diagnostics and early detection market.","Invested $36mm into R\u0026amp;D to date.","$200mm current deal pipeline with hospital systems.","Established distribution partnerships to reach 70,000 customers in 2024 for its Qx solution."]},"computed_metrics":{"total_amount_raised":0,"total_investors":0,"team_size":7,"featured_investor_count":7,"faq_count":2,"recent_post_count":2},"quick_facts":[{"claim_id":"claim-fact-1","value":"Realized $50mm in revenue.","citation":"https://wefunder.com/quantgene#claim-fact-1","observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-22T23:52:11Z"},{"claim_id":"claim-fact-2","value":"Combines genomics, AI and medical intelligence technology for universal cancer detection.","citation":"https://wefunder.com/quantgene#claim-fact-2","observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-22T23:52:11Z"},{"claim_id":"claim-fact-3","value":"Pole position to disrupt the $168B cancer diagnostics and early detection market.","citation":"https://wefunder.com/quantgene#claim-fact-3","observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-22T23:52:11Z"},{"claim_id":"claim-fact-4","value":"Invested $36mm into R\u0026amp;D to date.","citation":"https://wefunder.com/quantgene#claim-fact-4","observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-22T23:52:11Z"},{"claim_id":"claim-fact-5","value":"$200mm current deal pipeline with hospital systems.","citation":"https://wefunder.com/quantgene#claim-fact-5","observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-22T23:52:11Z"},{"claim_id":"claim-fact-6","value":"Established distribution partnerships to reach 70,000 customers in 2024 for its Qx solution.","citation":"https://wefunder.com/quantgene#claim-fact-6","observed_at":"2026-06-15T23:52:11Z","expires_at":"2026-06-22T23:52:11Z"}],"latest_fundraise":{"id":108027,"entity_id":"wefunder:fundraise:108027","state":"open","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":true,"funding_started_at":null,"funding_closed_at":null},"investor_memos":[],"team":[{"id":4139596,"entity_id":"wefunder:company_role:4139596","name":"Jo Bhakdi","title":"Founder, CEO and Chief Product Officer","role":"founder","profile_url":"https://wefunder.com/johannes.bhakdi"},{"id":4139612,"entity_id":"wefunder:company_role:4139612","name":"Robert Kunze","title":"CTO","role":"employee","profile_url":"https://wefunder.com/robert.kunze"},{"id":4139614,"entity_id":"wefunder:company_role:4139614","name":"Abdul Safi","title":"Head of Supply Chain and Field Operations ","role":"employee","profile_url":"https://wefunder.com/abdul.safi"},{"id":4139750,"entity_id":"wefunder:company_role:4139750","name":"Dr. Nicole Conradie","title":"Head of Genomic Laboratory R\u0026D ","role":"employee","profile_url":"https://wefunder.com/nicole.conradie"},{"id":4139753,"entity_id":"wefunder:company_role:4139753","name":"Dr. Darren Wight","title":"Head of Genomics R\u0026D","role":"employee","profile_url":"https://wefunder.com/darren.wight"},{"id":4139754,"entity_id":"wefunder:company_role:4139754","name":"Dr. Stefan Budach","title":"Head of Bioinformatics and Machine Learning","role":"employee","profile_url":"https://wefunder.com/stefan.budach"},{"id":5045222,"entity_id":"wefunder:company_role:5045222","name":"Bernar Bekirov","role":"employee","profile_url":"https://wefunder.com/bernar.bekirov"}],"featured_investors":[{"id":7697,"entity_id":"wefunder:company_investor_profile:7697","name":"Startup Health","profile_url":"https://wefunder.com/startup.health.1","endorsement_quote":"\"We have invested and worked with over 400 healthcare startups across 15 moonshots here at StartUp Health. It’s very rare to come across something with the scale and potential impact of Quantgene. Making genomics intelligent could be a game-changer in not only our fight against cancer but also in our fight with mental health issues, autoimmune and other diseases.\" Jamey Edwards, COO"},{"id":7696,"entity_id":"wefunder:company_investor_profile:7696","name":"Vikor Scientific","profile_url":"https://wefunder.com/vikor.scientific","endorsement_quote":"\"Quantgene has been pioneering genomics technology at an astonishing pace. I believe the team has built something incredible that can change the future of medicine.\" Shea Harrelson, Cofounder Vikor Scientific"},{"id":7731,"entity_id":"wefunder:company_investor_profile:7731","name":"Chip Campbell","bio":"Chip Campbell is an experienced angel investor in disruptive, innovative companies. He is focused on health \u0026amp; wellness, with a concentration in genomics, as well as technologies that underpin the secular growth trends shaping our world.","profile_url":"https://wefunder.com/chip.campbell","endorsement_quote":"\"Quantgene is one of my most exciting investments. Its technology and strategy has the potential to have a greater impact on cancer than anything else I have seen.\" Chip Campbell is an experienced angel investor in disruptive, innovative companies. He is focused on health \u0026amp; wellness, with a concentration in genomics, as well as technologies that underpin the secular growth trends shaping our world. Previously, Chip was an Executive Director at JP Morgan where he spent 15yrs in various capital markets roles."},{"id":7704,"entity_id":"wefunder:company_investor_profile:7704","name":"Michelle Le","profile_url":"https://wefunder.com/michelle.le.1","endorsement_quote":"\"I tragically lost my mother to gastric cancer, and I firmly believe that if Quantgene Qx had been accessible to her, she would still be here with us. This affects everyone, and it’s my most meaningful investment. We can’t just stand by and wait for bad things to happen - we have to support progress.\""},{"id":7700,"entity_id":"wefunder:company_investor_profile:7700","name":"Lyrical Partners","profile_url":"https://wefunder.com/lyrical.partners","endorsement_quote":"Lyrical Asset Management is an independently owned organization founded on the basis of a multi-decade friendship between our Founders. Our people, their character, and their judgment, naturally underpin all we do. We hope that, for the decades to come, our investors are as proud of and confident in our team as we are."},{"id":7705,"entity_id":"wefunder:company_investor_profile:7705","name":"Harry Nelson","profile_url":"https://wefunder.com/harry.nelson.1","endorsement_quote":"“I’ve had the privilege of advising and working with many genomic medicine pioneers, but none have had the combination of vision and ability to execute that Quantgene embodies. I would not bet against Quantgene.” Harry Nelson is the Founder and Managing Partner of Nelson Hardiman, LLP, the largest healthcare and life sciences specialty law firm in Los Angeles. Harry is the author of The United States of Opioids: A Prescription for Liberating a Nation in Pain, published by Forbes in March 2019, which received critical praise for changing the crisis-related conversation from spectacle to solutions. The book grew out of Harry’s work in opioid overdose and other crisis response in behavioral health. In 2017, Harry co-authored From ObamaCare to TrumpCare: Why You Should Care, an exploration of U.S. health policy past, present, and future aimed at moving beyond rhetoric and hand-wringing to bipartisan dialogue."},{"id":7699,"entity_id":"wefunder:company_investor_profile:7699","name":"Moore Capital ","profile_url":"https://wefunder.com/moore.capital.","endorsement_quote":"Moore Capital Management, LP is a global investment management firm headquartered in New York, New York. In September 2018, MCM had $10.2 billion in total assets under management."}],"relationships":[{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:53417","target_url":"https://wefunder.com/johannes.bhakdi"},{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:4215269","target_url":"https://wefunder.com/robert.kunze"},{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:4214735","target_url":"https://wefunder.com/abdul.safi"},{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:4217757","target_url":"https://wefunder.com/nicole.conradie"},{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:4217802","target_url":"https://wefunder.com/darren.wight"},{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:4217795","target_url":"https://wefunder.com/stefan.budach"},{"source_entity_id":"wefunder:company:151208","relation":"has_team_member","target_entity_id":"wefunder:user:4388704","target_url":"https://wefunder.com/bernar.bekirov"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11184","target_url":"https://wefunder.com/startup.health.1"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11183","target_url":"https://wefunder.com/vikor.scientific"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11211","target_url":"https://wefunder.com/chip.campbell"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11190","target_url":"https://wefunder.com/michelle.le.1"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11187","target_url":"https://wefunder.com/lyrical.partners"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11191","target_url":"https://wefunder.com/harry.nelson.1"},{"source_entity_id":"wefunder:company:151208","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11185","target_url":"https://wefunder.com/moore.capital."},{"source_entity_id":"wefunder:company:151208","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:170103","target_url":"https://wefunder.com/feed/170103"},{"source_entity_id":"wefunder:company:151208","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:169759","target_url":"https://wefunder.com/feed/169759"},{"source_entity_id":"wefunder:company:151208","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:108027"}],"faq":[{"question":"Do you have any patents?","answer":"Hi Grigore, thanks for supporting our mission!! Yes, we have 4 patents, two specifically covering out liquid biopsy cancer detection technology (genomics + algorithms). However, patents are only a small fraction of the relevant IP we build. The key to our QX system is a comprehensive medical intelligence system that connects genomics, imaging results and other medical data into a full picture of lifetime AND acute cancer risks by organ and coordinates all relevant follow-up diagnostics to ach..."},{"question":"I’m excited about researching your company as a possible investment and I have several questions. What is your annual income and net profit? Does the company have any debt? Who are your competitors? Based on current sales what are your growth projections for revenue out to 203...","answer":"Jude, thank you for your questions! We had $2.5mm revenue in 2023. We are transitioning our commercial product mix from laboratory and pandemic-related to a full focus on cancer this year going forward, which will lead to a decline in 2024 and then a projected exponential growth beginning in 2025. You can see our financial projections on the WeFunder page. Our strategy is focused around large hospital systems who want our turnkey solutions inhouse, both for reimbursed genetic testing and for ..."}],"recent_posts":[{"id":170103,"entity_id":"wefunder:feed_item:170103","title":"We just partnered with GetLabs for nationwide at-home blood draws for Universal Cancer Detection","preview":"Amazing stuff, Get Labs is the best provider for at-home blood draws. It goes well with QX Universal Cancer Screening and makes it even more convenient. We are working on the press release, stay tuned over the coming weeks. We are also working on a major partnership with a nationwide MD group, which will be even more important. Universal Detection is coming to all!","published_at":"2024-01-20T21:36:21Z","canonical_url":"https://wefunder.com/feed/170103"},{"id":169759,"entity_id":"wefunder:feed_item:169759","title":"Let's End Cancer in 2024","preview":"We are LIVE and just kicked off 2024 with the most exciting campaign in crowdfunding history. Let's DO THIS!","published_at":"2024-01-02T21:09:29Z","canonical_url":"https://wefunder.com/feed/169759"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-16T02:04:52Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T23:52:11Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T23:52:11Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-05-01T13:45:52Z","as_of":"2026-06-16T02:04:52Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-05-01T13:45:52Z","as_of":"2026-06-16T02:04:52Z","confidence":"medium"}}}}}}